NCT06189820RecruitingPhase 2
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 22 Nov 2023
- Start date
- 9 Mar 2023
- Primary completion date
- 9 Mar 2027
- Lead sponsor
- Erasme University Hospital
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT06189820
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From 9 Mar 2023 to the primary completion date, 9 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Other
- Pregnant or nursing patients
- Patients with an active lung neoplasm or any active neoplasm for blood samples
Who the study is looking for
- Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medecine Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.